Director, US Medical, New Product Planning

By clicking the “Apply” button, I understand that my employment application process with Takeda will commence and that the information I provide in my application will be processed in line with Takeda’s Privacy Notice and Terms of Use. I further attest that all information I submit in my employment application is true to the best of my knowledge.

Job Description

About the role:

The Director, US Medical, New Product Planning is a critical role within the US Medical organization that reports to the Sr. Director, US Medical, New Product Planning, and is accountable for the development and execution of comprehensive and integrated US-specific medical launch strategies for early assets in development (typically Phase 2 and early Phase 3) within the assigned Therapeutic Area portfolio/assets. This is an individual contributor role based in our Lexington, MA office (hybrid).

How you will contribute:

• Serve as Subject Matter Expert (SME) representing US Medical at the USBU and Global level on relevant internal meetings, understanding the US scientific and medical landscape and patient/medical journey for assigned pipeline assets to inform launch strategy.

• Partner with USBU New Product Planning team, USBU Franchise leadership, US Medical Functional leaders, and TA Medical Franchise Heads to develop the product profile, understand customer needs, competitive landscape, and other market considerations.

• Collaborate with relevant Global functions to highlight US-specific needs to influence clinical study endpoint decisions to ensure US needs are represented in ongoing clinical development program, or where appropriate, other Global-driven initiatives.

• Serve as medical and scientific in-house expert for assigned TA and asset, working with various US functions such as USBU NPP, USBU NPP Market Access, US Medical NPP Value & Evidence Generation (VEG), US Medical TA leads, US Medical Directors

• Partner with stakeholders across Takeda (e.g. R&D, Global Product Launch Strategy, USBU, etc.,) to develop early asset strategy and medical launch plans (strategies and tactics), ensuring the US medical stakeholder voice is considered and included. This includes, but is not limited to, gathering medical insights, developing appropriate and compliant resources for field medical development and training, and compliantly supporting various early commercial activities.

• Represent US Medical as core member on cross-functional teams with USBU Franchise/US NPP to drive execution of launch planning

• Participate as a member Global sub-teams (e.g. Commercial subteam, Clinical subteam, Medical subteam, Publications etc.) as appropriate, bringing a US medical perspective to the program and relevant workstreams.

Evidence Generation:

• Collaborate with the US Medical Value and Evidence Generation (VEG) team, Global Evidence and Outcomes (GEO), Global Health Economics (GHE), Global Patient Access (GPA) and other stakeholders to identify US-specific gaps and develop robust integrated evidence generation plans for the US

Medical Content:

• Develop early US medical strategy and plans

• Liaise with Global Medical counterparts to develop timely and appropriate materials for the US

• Develop and/or adapt internal training materials for US Medical/USBU

• Support medical review of any appropriate materials as part of medical and commercial review processes.

External Engagement:

• Develop KOL engagement plans in collaboration with US Field Medical, Therapeutic Area (TA) leaders and Global Medical

• Gather KOL insights that inform medical launch strategies through advisory boards, professional associations/meetings and conferences etc.; manage global interactions with US KOLs and vice versa

• Partner with US Strategic Medical Alliances group on external partnership, as appropriate (e.g., external affairs/g